| Completed | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 Hepatic Impairment | Phase 1 | 2020-01-09 |
| Completed | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989 Hepatic Impairment | Phase 1 | 2020-01-08 |
| Terminated | Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation Respiratory Syncytial Virus Infections | Phase 2 | 2019-12-26 |
| Completed | A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negat Hepatitis B, Chronic | Phase 2 | 2019-11-06 |
| Completed | A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chro Hepatitis B, Chronic | Phase 2 | 2019-08-01 |
| Completed | A Study of JNJ-73763989 in Healthy Japanese Adult Participants Healthy | Phase 1 | 2019-07-04 |
| Completed | A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants Healthy | Phase 1 | 2019-05-15 |
| Completed | A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a Hepatitis B, Chronic | Phase 1 | 2018-04-18 |
| Completed | An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Hepatitis B | Phase 2 | 2018-02-13 |
| Completed | A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single Healthy | Phase 1 | 2017-03-27 |
| Completed | A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Healthy, Hepatitis, Chronic | Phase 1 | 2015-12-17 |
| Terminated | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ- Respiratory Syncytial Virus Infections, Virus Diseases | Phase 1 | 2015-12-04 |
| Completed | A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat i Healthy | Phase 1 | 2015-11-01 |
| Completed | Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Comp Healthy | Phase 1 | 2015-10-01 |
| Completed | A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF Immunodeficiency Virus Type 1, Human | Phase 3 | 2015-07-06 |
| Active Not Recruiting | A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who P Human Immunodeficiency Virus Type 1 | Phase 2 | 2015-07-06 |
| Completed | Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Do Healthy | Phase 1 | 2015-06-01 |
| Completed | A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regim Hepatitis C, Chronic | Phase 2 | 2015-05-19 |
| Completed | Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JN Respiratory Syncytial Virus Infections | Phase 2 | 2015-05-07 |
| Completed | A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidat Healthy | Phase 1 | 2015-04-28 |
| Completed | A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Pa Healthy | Phase 1 | 2015-04-01 |
| Completed | Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants Healthy | Phase 1 | 2015-03-04 |
| Completed | TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infe HIV-1 Infections | Phase 3 | 2011-08-08 |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) HIV-1 | Phase 2 | 2011-01-01 |
| Completed | TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Ch HIV-1 Infections | Phase 2 | 2010-10-13 |
| Active Not Recruiting | TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants HIV Infections, HIV-1 | Phase 3 | 2009-12-09 |
| Approved For Marketing | Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participa HIV | — | — |
| No Longer Available | Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Im Respiratory Syncytial Virus | — | — |